Oral Targeted Anticancer Medication Trends and Modifiable Use Predictors

As the number of highly priced oral targeted anti-cancer medications (OTAM) is increasing and evidence on clinical benefits of OTAM is increasingly limited, we investigate regulatory characteristics of OTAM, and patterns and predictors of OTAM use. Policy makers could use the results of this study to design interventions to optimize OTAM use and spending. Findings should help doctors and health plans detect, monitor, and mitigate risk of uncertain clinical benefit, harm, and value of OTAM spending. Researchers could use the results to design and test interventions that optimize cancer treatment with oral medications under newer types of health benefits.